Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
07/2003
07/02/2003EP1224180B1 Substituted azoles
07/02/2003EP1210346B1 New active marine alkaloids
07/02/2003EP1171444B1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
07/02/2003EP0944582B1 Ketobenzamides as calpain inhibitors
07/02/2003EP0910246A4 Use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
07/02/2003EP0900211B1 Thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors
07/02/2003EP0879282B1 Immunotherapy using cytotoxic t lymphocytes (ctl)
07/02/2003EP0781343B1 Retroviral vector hybrids and the use thereof for gene transfer
07/02/2003EP0626864B1 Topical composition containing hyaluronic acid and nsaids
07/02/2003CN1427952A Docosahexaenoic acid as retinoid X receptor and uses thereof
07/02/2003CN1427891A Anti-EGFRvIII scFv with improved cytotoxi city and yield, immunotoxins based thereon, and methods of use thereof
07/02/2003CN1427889A Hybrid cells obtainable from antigen presenting cells
07/02/2003CN1427844A Bis-(N,N'-bis-(2-haloethyl) amino) phosphoramidates as antitumor agents
07/02/2003CN1427837A Ortho-substituted anthranilic acid amides and their use as medicaments
07/02/2003CN1427825A Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
07/02/2003CN1427719A Use of substituted acryloyl distamycin derivatives in treatment of tumors associated with high levels of glutathione
07/02/2003CN1427076A Combined deletion 19 Kda, 55KDA, E1B code sequence recombination adenovirus construction body and its use
07/02/2003CN1427075A Recombination adenovirus construction body with deletion E1A code sequence and its use
07/02/2003CN1427008A Method of designing and selecting natural siRNA as gene medicine and medicine formulation
07/02/2003CN1426795A Composition for increasing leukocyte and its application
07/02/2003CN1426783A Application of evodiamine in the preparation of medicine
07/02/2003CN1113102C Antitumer preparation
07/02/2003CN1113067C New active peptide and production thereof
07/01/2003US6586623 Thiol-based NAALADase inhibitors
07/01/2003US6586618 Amination 1,3-dihydoxynaphthalene, then blocking, iodination, alkylation, cyclization and deblocking to give (5-hydroxy-3-amino-1-(S)-(chloromethyl)-1,2-dihydro-3H-benz(e)indole), used as chemical intermediates of antitumor agents
07/01/2003US6586571 Isolated polypeptide that binds to MORT-1 (mediators of receptor toxicity) protein
07/01/2003US6586476 Methods for the treatment of nephro-disorders using aminothiol compounds
07/01/2003US6586474 Amidino compounds useful as nitric oxide synthase inhibitors
07/01/2003US6586471 Halogenated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
07/01/2003US6586467 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus
07/01/2003US6586460 Administering heterocyclic ethers or sulfides to induce apoptosis, cell differentiation and as anticarcinogenic agents
07/01/2003US6586456 Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide
07/01/2003US6586455 Treatment of liposarcomas using a combination of thiazolidinediones and retinoid X receptor selective agonists
07/01/2003US6586448 Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders
07/01/2003US6586447 Farnesyl protein transferase inhibitors such as 4-(6-(4-Cyano -phenyl)-3,3-bis-(1H-imidazol-4-ylmethyl)-2-oxo-2,3- dihydro-indol-1-ylmethyl)-N,N-dimethyl benzenesulfonamide used as anticarcinogenic agents
07/01/2003US6586445 Racemic mixtures of 1,2,3,4-tetra hydro-1-(4-methoxyphenyl)-3 -(4-phenyl-1H-imidazol-2-yl)-9H- pyrido(3,4-b)indole, which bind to somatostatin receptors and block sodium channel modulators; antidiabetic, antiinflammatory agents; diarrhea
07/01/2003US6586442 Benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them
07/01/2003US6586432 Neurokinin-1 receptor antagonists
07/01/2003US6586429 For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders
07/01/2003US6586428 Combined preparations comprising morpholine anthracyclines and anticancer agent
07/01/2003US6586424 Anticancer agents; anticholesterol agents
07/01/2003US6586423 Tyrosine kinase inhibitors
07/01/2003US6586409 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
07/01/2003US6586402 Leucine replaced by neopentylglycine or adamantylalanine
07/01/2003US6586397 Polypeptides encoding tyrosine kinase containing immunoglobulin and endithelial growth factor homology domains; induce vascularization
07/01/2003US6586244 Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
07/01/2003US6586242 TAO protein kinases and methods of use therefor
07/01/2003US6586015 Use of Phyllanthus for treating chronic inflammatory and fibrotic processes
07/01/2003US6585968 Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
07/01/2003US6585956 Dendritic-platinate drug delivery system
07/01/2003CA2166243C Apoptosis-modulating composition containing a factor modifying intracellular methional and malondialdehyde rates
06/2003
06/26/2003WO2003052106A1 Method of screening compounds
06/26/2003WO2003052096A1 Mtehod of analyzing gene expression
06/26/2003WO2003052095A2 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
06/26/2003WO2003052089A1 Disruption of the glutathione s-transferase-omega-1 gene
06/26/2003WO2003052058A2 Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051926A2 Anti-cd7 immunotoxin as fusion protein
06/26/2003WO2003051922A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
06/26/2003WO2003051921A1 Chemokine mutants acting as chemokine antagonists
06/26/2003WO2003051917A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003WO2003051905A2 Taojiks as modifiers of the beta-catenin pathway and methods of use
06/26/2003WO2003051903A1 Androstane derivative having substituent in 7- and 17-positions
06/26/2003WO2003051900A1 Derivatives of isoindigo, indigo and indirubin and use in treating cancer
06/26/2003WO2003051893A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051888A1 6-aminomorphinane derivatives, method for the production and use thereof
06/26/2003WO2003051887A1 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors
06/26/2003WO2003051886A1 Pyrazolopyridazine derivatives
06/26/2003WO2003051885A1 Nitrogen-containing heterocyclic compounds and use thereof
06/26/2003WO2003051883A1 Indole derivative
06/26/2003WO2003051880A1 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
06/26/2003WO2003051879A1 Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
06/26/2003WO2003051878A1 Quinolinones as prostaglandin receptor ligands
06/26/2003WO2003051877A1 2-substituted pyrrolo[2.1-a]isoquinolines against cancer
06/26/2003WO2003051872A1 Ethylene diamine derivatives and their use as orexin-receptor antagonists
06/26/2003WO2003051869A1 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
06/26/2003WO2003051868A1 Lactams as tachykinin antagonists
06/26/2003WO2003051864A1 Isoflavonoid conjugates, compositions thereof and therapeutic methods involving same
06/26/2003WO2003051863A1 SUBSTITUTED 6H-DIBENZO[c,h]CHROMENES AS ESTROGENIC AGENTS
06/26/2003WO2003051854A1 Thiadiazoline derivative
06/26/2003WO2003051844A1 2,3-dihydro-1h-quinolin-4-one oxime derivative and inhibitors of the induction of heat shock protein expression
06/26/2003WO2003051842A2 Compositions decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051841A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051838A2 Protein kinase inhibitors
06/26/2003WO2003051837A2 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
06/26/2003WO2003051828A2 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
06/26/2003WO2003051825A1 Human adam-10 inhibitors
06/26/2003WO2003051807A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051805A2 Substituted phenyl naphthalenes as estrogenic agents
06/26/2003WO2003051804A1 Novel substance having antitumor/anti-inflammatory activity
06/26/2003WO2003051454A2 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
06/26/2003WO2003051401A2 Stabilised mrna tumour vaccine
06/26/2003WO2003051400A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003WO2003051388A2 Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
06/26/2003WO2003051384A1 Method for treating cervical cancer
06/26/2003WO2003051383A2 Use of hmgb proteins and nucleic acids that code therefor
06/26/2003WO2003051382A1 Method of inducing apoptosis and compositions therefor
06/26/2003WO2003051377A1 Method for preparing fetuin and polypeptide to induce apoptosis
06/26/2003WO2003051360A1 Cis-imidazolines as mdm2 inhibitors
06/26/2003WO2003051359A1 Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
1 ... 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 ... 2211